Blog
RSS FeedPosted by Michael Wonder on 16 Jan 2020
NICE ‘OK’ for Lynparza
16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...
Posted by Michael Wonder on 16 Jan 2020
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 15 Jan 2020
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata
15 January 2020 - Cost-effectiveness watchdog issues a round of draft and final guidance. ...
Posted by Michael Wonder on 15 Jan 2020
NICE rejects Keytruda, asks for more information
15 January 2020 - NICE has published a new draft guidance not recommending MSD’s cancer blockbuster Keytruda (pembrolizumab) for untreated ...
Posted by Michael Wonder on 03 Jan 2020
Additional evidence needed to assess histology-independent cancer drugs says paper co-authored by NICE staff
2 January 2020 - Paper looks at how histology-independent cancer drugs might be appraised. ...
Posted by Michael Wonder on 02 Jan 2020
Tecentriq hit with draft NICE rejection
2 December 2020 - NICE has issued a new draft guidance, advising against the use of Roche's Tecentriq (atezolizumab) for ...
Posted by Michael Wonder on 02 Dec 2019
NICE grants Lynparza expansion for advanced ovarian cancer
2 December 2019 - Lynparza (olaparib), the joint MSD and AstraZeneca cancer drug, has been granted an expansion by NICE ...
Posted by Michael Wonder on 28 Nov 2019
Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund
28 November 2019 - Around 3,200 women in England could be eligible for treatment. ...
Posted by Michael Wonder on 25 Nov 2019
Boris Johnson pledges £500 million for cutting-edge medicine as PM plans to expand Cancer Drugs Fund to fight dementia and motor neurone disease
23 November 2019 - Prime Minister promises to give patients faster access to innovative medicines. ...
Posted by Michael Wonder on 31 Oct 2019
NICE terminates another two assessments for cancer medicines
30 October 2019 - One medicine is from Janssen; the other is from Eli Lilly. ...
Posted by Michael Wonder on 22 Oct 2019
Roche app allows access to latest cancer guidelines
21 October 2019 - Roche has launched an app allowing access to the latest guidelines covering the most common forms ...
Posted by Michael Wonder on 11 Oct 2019
Another treatment option for ovarian cancer approved for the Cancer Drugs Fund
11 October 2019 - An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE ...
Posted by Michael Wonder on 03 Oct 2019
NICE looks to company to ensure a new treatment for advanced breast cancer with significant unmet need is cost-effective
3 October 2019 - Draft guidance published today by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) ...
Posted by Michael Wonder on 25 Sep 2019
Children with cancer are missing out on precision medicine, study finds
24 September 2019 - Only a small number of children with solid tumour cancers are able to access targeted precision ...
Posted by Michael Wonder on 23 Sep 2019
NICE numbers at 20 – a closer look at cancer
23 September 2019 - There has been continual interest in what the UK’s health technology assessment agency, NICE, has said ...